ZYUS Life Sciences Corporation
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries,… Read more
ZYUS Life Sciences Corporation (ZLSCF) - Net Assets
Latest net assets as of September 2025: $-12.97 Million USD
Based on the latest financial reports, ZYUS Life Sciences Corporation (ZLSCF) has net assets worth $-12.97 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.85 Million) and total liabilities ($23.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-12.97 Million |
| % of Total Assets | -119.53% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 255.33 |
ZYUS Life Sciences Corporation - Net Assets Trend (2022–2024)
This chart illustrates how ZYUS Life Sciences Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ZYUS Life Sciences Corporation (2022–2024)
The table below shows the annual net assets of ZYUS Life Sciences Corporation from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-5.34 Million | -123.12% |
| 2023-12-31 | $23.11 Million | +387.53% |
| 2022-12-31 | $4.74 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ZYUS Life Sciences Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7639600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $168.65 Million | % |
| Total Equity | $-5.34 Million | 100.00% |
ZYUS Life Sciences Corporation Competitors by Market Cap
The table below lists competitors of ZYUS Life Sciences Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mas Murni Indonesia Tbk
JK:MAMI
|
$24.24 Million |
|
Hwashin Precision Engineering Co. Ltd
KQ:126640
|
$24.25 Million |
|
T.S. Investment Corp.
KQ:246690
|
$24.25 Million |
|
Appro Photoelectron Inc.
TWO:6560
|
$24.25 Million |
|
SD Standard Drilling PLC
OL:SDSD
|
$24.23 Million |
|
Shenguan Holdings (Group) Limited
F:S2N
|
$24.23 Million |
|
Dhampur Bio Organics Limited
NSE:DBOL
|
$24.22 Million |
|
Group Ten Metals Inc
OTCQB:PGEZF
|
$24.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ZYUS Life Sciences Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 23,114,000 to -5,344,000, a change of -28,458,000 (-123.1%).
- Net loss of 33,805,000 reduced equity.
- New share issuances of 3,313,000 increased equity.
- Other factors increased equity by 2,034,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-33.80 Million | -632.58% |
| Share Issuances | $3.31 Million | +61.99% |
| Other Changes | $2.03 Million | +38.06% |
| Total Change | $- | -123.12% |
Book Value vs Market Value Analysis
This analysis compares ZYUS Life Sciences Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $0.07 | $0.60 | x |
| 2023-12-31 | $0.33 | $0.60 | x |
| 2024-12-31 | $-0.07 | $0.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ZYUS Life Sciences Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7028.07%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-234.78%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -520.08% | -8274.16% | 0.00x | 13.65x | $-25.13 Million |
| 2023 | -184.26% | -12134.19% | 0.01x | 1.80x | $-44.90 Million |
| 2024 | 0.00% | -7028.07% | 0.03x | 0.00x | $-33.27 Million |
Industry Comparison
This section compares ZYUS Life Sciences Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ZYUS Life Sciences Corporation (ZLSCF) | $-12.97 Million | -520.08% | N/A | $24.23 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |